of patient inactivity related to the presence of multiple comorbidities. Third, surveillance studies in surviving patients may underestimate the true incidence and clinical relevance of the abnormalities.
Both leaflet immobility and valve thrombosis have been diagnosed in patients treated with either TAVR or SAVR (Table) . Issues to be considered include the fact that the absolute number of patients with these findings reported, although still low, may be due to the fact that the reported incidence is low and without routine surveillance with sensitive imaging modalities is underdiagnosed. In addition, the number of different specific bioprosthetic valve designs for TAVR and SAVR is varied, making scientific assessment of whether the findings are device specific or class related difficult. Still other issues include the lack of standardized definitions of valve dysfunction, protocols for detection, and concerns about survivorship bias in surveillance studies.
VALVE LEAFLET IMMOBILITY
Leaflet immobility can be detected by transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) and has been seen at open redo valve surgery. The terms leaflet immobility and valve thrombosis are not necessarily interchangeable because the former may be the result of not only thrombus but also structural valve deterioration, pannus formation, and incomplete or noncircular stent deployment. Recently, 4-dimensional computerized tomographic (4DCT) imaging has been used more frequently in patients being treated with TAVR both for cause and as surveillance imaging. Leaflet immobility has been defined as "diffuse thickening of ≥1 THV [transcatheter heart valve] cusps identifiable in both double-oblique axial and multiplanar reformatted reconstructions." 7 Other authors have expanded the definition to include mild (<50% reduction), moderate (50%-70% reduction), severe (>70% reduction), and complete immobility of at least 1 valve leaflet. 1 Specific terminology has been developed related to the findings: hypoattenuated leaflet thickening (HALT) and hypoattenuation affecting motion. Whether the thickening is a precursor of subsequent abnormal motion remains unclear. With echocardiography used for evaluation, cusp thickness, defined as "thickness >2 mm or significantly thicker compared to the finger print 'baseline index' thickness findings," 8 and visual abnormal cusp motion can also be assessed. There are no scientifically controlled studies comparing the relative effectiveness of 4DCT, TEE, and TTE in the detection of either leaflet immobility or valve thrombosis. Small series have documented differences, with TEE felt to be more sensitive than TTE 8 and 4DCT felt to be better than TEE. 1, 7 Anecdotal experience in many clinical practices has led to 4DCT being the default best test for the detection of leaflet thickening, and thrombus TEE imaging is felt to be more sensitive for determining leaflet immobility than TTE. 4DCT with multislice high-resolution scanners with appropriate postprocessing software is the diagnostic modality used for surveillance of these findings in the 2 US Food and Drug Administration-approved randomized controlled trials of low-risk patients with aortic stenosis randomized to either TAVR or SAVR (NCT02675114 and NCT02701283) (Figure 1 ). The reduced leaflet immobility was seen in patients with a variety of different bioprostheses and both TAVR and SAVR. The number of clinical events, including stroke and transient ischemic attacks, was very small and not different in the clinical trial between patients with and those without leaflet immobility. However, in the pooled registries, there was a difference with an increase in clinical events in patients with abnormal leaflet function (P=0.007), although only 4 total events occurred. Overall, therapeutic anticoagulation with warfarin was associated with a decreased incidence of leaflet immobility. Other important findings included the following. First, in a very small subset of 20 patients with leaflet immobility who underwent follow-up imaging, restoration of leaflet function was documented in those receiving anticoagulation. Second, there was an absence of elevated aortic valve mean gradients in patients with reduced leaflet motion. Third, TTE was insufficiently sensitive, being limited in its ability by inadequate visualization within the valve stent frame to assess leaflet motion. An issue with this study was the lack of definitive pathological confirmation of the pathophysiology of the leaflet immobility. In a larger, more recent study, Pache et al 27 evaluated the frequency of HALT in 156 consecutive patients being treated with a SAPIEN 3 TAVR valve. CT angiography was performed at a median of 5 days after TAVR. For this study, HALT was defined as hypoattenuated thickening but with or without rigidity of ≥1 leaflets identified in ≥2 projections. HALT was identified in 16 patients (10.3%; 95% confidence interval, 5.5-15.0) but was subclinical in all. No baseline or procedural variables were associated with increased risk of HALT. Thirteen of the 16 patients were subsequently treated with full anticoagulation in addition to clopidogrel, and this regimen was associated with resolution in the majority of these patients.
VALVE THROMBOSIS
Valve thrombosis has been documented in selected case series with both TAVR and SAVR. 1, 4, [7] [8] [9] [10] [11] [12] 14, 15, 27 For detection of valve thrombus, both 4DCT and echocardiographic studies have been performed. 4, [7] [8] [9] [10] 12, 27 With the former, thrombosis has been defined as a low attenuating mass attached to THV (transcatheter heart valve) cusps. For this, CT attenuation values of the masses were measured using a region of 0.1 cm. 7, 27 This CT criterion also includes leaflet thickening. Documentation of features diagnostic of valve thrombus by echocardiography has been called elusive. 9 More frequently, with echocardiography, the pattern of thickening and worsening hemodynamic transcatheter gradients has been felt to be a criterion for valve thrombus. 12 However, it remains unclear whether a specific gradient threshold can be used to possibly detect leaflet thrombosis in the absence of visible thrombus. For evaluation of valve thrombosis, apart from 4DCT images of a discrete mass in the absence of signs/symptoms of infective endocarditis, diagnosis relies on a constellation of imaging abnormalities, including a possible thrombus plus leaflet thickening. The gold standard from the surgical literature has been that valve thrombosis is any "thrombosis not caused by infection attached to or near an operated valve that occludes part of the blood flow path, interferes with valve function or is sufficiently large to warrant treatment" 11 or postmortem confirmation. As the field continues to evolve, additional standard definitions include resolution of the imaging abnormality after treatment or resolution of abnormal transcatheter gradients with vitamin K antagonists. 4 De Marchena et al 4 documented 3 postmortem cases that were found to have thrombus on at least 3 TAVR leaflets. An additional case was a patient with abnormal transvalvular gradients that normalized after vitamin K antagonist. None of these abnormalities had been visualized by either TTE or TEE. These authors summarized an additional 18 case reports of early valve thrombosis. Of those 18 other reported cases, there was surgical confirmation in 3 and autopsy confirmation in an additional 3 patients. Ten of the remaining patients had improved hemodynamics with reduction of the transvalvular gradient on treatment with anticoagulants, whereas the remaining 2 patients had symptomatic improvement.
In the largest series, Hansson et al 28 evaluated transcatheter aortic valve thrombosis in 405 patients treated with an Edwards Sapien XT or Sapien 3 TAVR prosthesis. These patients underwent multidetector CT (MDCT) in addition to echocardiography 1 to 3 months after TAVR. The MDCT scans were evaluated for HALT, which was felt to be indicative of THV thrombosis. With the use of this definition, THV thrombosis was identified in 28 patients (7%) at a median interval of 43 days (range, 28-57 days). In 23 of these patients, the THV thrombus was deemed to be subclinical, whereas in the remaining 5 patients, it was clinically overt. In a multivariate analysis, a 29-mm THV was associated with increased thrombosis (relative risk, 2.89; 95% confidence interval, 1.44-5.80), and no post-TAVR warfarin therapy (relative risk, 5.46; 95% confidence interval, 1.68-17.7) was a predisposing factor. In patients with detected THV thrombus, subsequent treatment was at the discretion of the primary physician. Warfarin alone or in combination with antiplatelet therapy was used in the majority and resulted in complete resolution in 85% of cases.
Valve thrombosis has also been studied in SAVR. Typically, these evaluations have included patients selected for repeat cardiac surgery with the bias of being diagnosed for cause rather than by surveillance. Brown et al 11 evaluated the outcome of a clinical series of 4568 patients receiving a SAVR bioprosthesis over a period from 1993 to 2009. During this time, 8 patients underwent reoperation to replace the valve because of thrombus that had resulted in functional aortic stenosis (Figure 2) . The frequency of the event varied. depending on the specific bioprosthesis: 1.26% for the Biocor porcine (St. Jude Medical) valve, 0.37% for the Mosaic (Medtronic Inc, Minneapolis, MN) porcine valve, and 0.84% for the Hancock (Medtronic, Inc) porcine valve. They found no case of valve thrombus in patients who had received a pericardial tissue valve. In these patients with definite surgically confirmed thrombus, the median time to reoperation was 398 days (range, 106-626 days). Whether this represents a finding that SAVR thrombosis has a different time course than TAVR thrombosis is unknown. The potential for a differing incidence of thrombus depending on the specific valve type was also assessed in a single-center study of 1751 patients who received a single stented aortic bioprosthesis between 2007 and 2012. 18 In this series, 43% were porcine valves and 57% were bovine valves. Obstructive thrombus was defined by an increase in mean pressure gradient ≥20 mm Hg or a decrease in velocity ratio ≥0.05 m/s when confirmed by CT, return to baseline hemodynamic parameters with treatment by vitamin K antagonist, or histology at the time of reoperation. This was present in 17 patients with a porcine SAVR (2.3%) and in no patients with a bovine valve.
A confounding issue with SAVR is distinguishing between structural failure due to pannus formation and thrombus. This has important implications for treatment. Egbe et al 8 evaluated 397 consecutive cases of surgically explanted bioprostheses. In this series, there were 46 cases (11.6%) of bioprosthetic valve thrombosis; in 29 of these cases, it was localized to the aortic bioprosthesis. The authors compared clinical and echocardiographic characteristics of thrombosed and degenerative bioprostheses. Although the study included other valve positions in addition to the aortic valve, the authors found that bioprosthetic valve thrombosis in patients referred for surgical interventions could be considered most likely on the basis of the findings of >50% increase in mean echocardiographic Doppler gradients from baseline, increased cusp thickness, and abnormal cusp mobility. However, this study antedated the widespread availability or application of 4DCT imaging.
CLINICAL CONTEXT
Although the total number of patients evaluated for the diagnosis of leaflet immobility and valve thrombus is relatively small, there is great concern because of the number of patients at potential risk for clinical events related to these abnormalities or for the risks of treatment aimed at resolving the abnormal imaging findings. The latter issue is exemplified by TAVR performed in patients at high surgical risk for conventional SAVR. In this setting, patients may be at high risk for bleeding complications. Accordingly, concern has been expressed that because of leaflet abnormalities, which may have minimal clinical consequences, a large number of these patients may be started on anticoagulants needlessly. However, in the 3 largest series reported that included in aggregate 70 patients, full anticoagulation led to complete or partial resolution of the imaging abnormality in >75% of patients. 15, 27, 28 This must be balanced against the risk of bleeding for individual patients. The current American College of Cardiology/American Heart Association valvular heart disease guidelines 21 for SAVR recommend anticoagulation with a vitamin K antagonist for 3 months after bioprosthetic valve placement (Class IIb, Level of Evidence B). These recommendations may be extended to TAVR, although some of the patients have significant contraindications to this adjunctive therapy because of bleeding hazard. The role of novel oral anticoagulants is uncertain but is the focus of 2 randomized controlled trials of rivaroxaban and apixaban for TAVR (NCT02556203 and NCT02664649).
Additional reasons for concern relate to the fact that lower-risk patients who are good surgical candidates are now being treated with TAVR. 22, 23 If leaflet immobility is a major clinical issue with TAVR, its incidence appears to be higher than early thrombosis seen with SAVR, although this is still unknown. It is also postulated that early valve thrombosis may be the pathophysiological mechanism of early structural valve deterioration, which would be of greater consequence in younger patient populations. A final issue relates to expansion of the use of TAVR to patients for the treatment of previously placed bioprosthetic SAVR valves, that is, valve in valve (VinV). Tissue surgical valves have become the standard in patients >65 to 70 years of age because, although the projected life of these specific devices is less than that seen with mechanical prostheses, it has been felt that long-term anticoagulation is not required. These surgical bioprostheses may develop valve deterioration and may require reintervention. In this setting, there are multiple issues to be considered: The patients are older than they were at the index procedure, often with more comorbidities, and they have already undergone 1 sternotomy, making a less invasive procedure more attractive. Tourmousoglou et al 5 reviewed the question of TAVR VinV versus reoperative SAVR. They identified 12 articles that provided the best evidence, although no trials were randomized. TAVR VinV was found to be clinically effective in the short term and could be an acceptable approach in selected high-risk patients, but there were wide ranges in 30-day mortality for both, ranging from 2.3% to 15.5% for reoperative SAVR and from 0% to 17% for VinV TAVR. As the population ages, VinV becomes more attractive; the frequency of TAVR in the Society of Thoracic Surgeons/ American College of Cardiology Transcatheter Valve Therapy Registry is ≈5% and growing. There is concern that patients with VinV may be at higher risk for valve thrombosis, which would have important implications particularly for patients with small failing SAVR bioprostheses.
CLINICAL IMPLICATIONS
Many uncertainties remain in this field. Important practical considerations include the following:
1. What is the optimal imaging modality? At the present time, MDCT is felt to be both the most sensitive and specific for imaging the leaflets, particularly in contrast to TTE. Use in patients must take into consideration the radiation exposure and requirement for contrast, as well as the timing and frequency. In symptomatic patients, those who have recurrent congestive heart failure, stroke, or transient ischemic attack, MDCT should be performed if possible. In asymptomatic at-risk patients, given the frequency of the abnormal finding, it is reasonable to consider 1 postoperative MDCT during the first 3 months to act as a baseline. Per protocol in many institutions, echocardiography is performed yearly. In this regard, TEE is felt to be superior to TTE but carries the risk of a more invasive procedure. 2. If HALT is seen, what should the treatment be, if any? On the basis of the available selected data, anticoagulation is associated with resolution of the abnormality and therefore may be considered in the absence of contraindications. After anticoagulation for 3 to 6 months, it is reasonable to repeat the imaging. 3. Should there be routine post-TAVR adjuvant therapy? Two trials evaluating the role of novel oral anticoagulants are underway. In the absence of well-designed scientific data, an empirical course of warfarin anticoagulation after TAVR, similar to that currently used with SAVR, provided that the bleeding risk is not excessive is reasonable.
CONCLUSIONS
The issues of leaflet immobility and valve thrombosis in bioprosthetic aortic valve replacement are interrelated and complex, but given the large number of patients at risk, they are of critical importance. These concerns have led to a US Food and Drug Administration clinical perspective that concluded "after careful review of all available data…that the benefits of using these devices for the currently approved indication continue to outweigh the risks" and that "the reported occurrence of reduced leaflet motion…is an early signal of unknown clinical significance." 3 Further study of the issues was urged, particularly because the TAVR devices are increasingly used in lower-risk patients with severe aortic stenosis. Two randomized US trials have been initiated, both of which are enrolling low-risk patients. PARTNER 3 (Placement of Aortic Transcatheter Valves) is enrolling 1228 patients with severe aortic stenosis and Society Thoracic Surgeons risk prediction score <4 to SAVR versus TAVR with a 1-year primary end point of death, stroke, and rehospitalization. CoreValve EVOLUT R trial (CoreValve Evolut R Transcatheter Aortic Valve) is enrolling 1200 patients with severe aortic stenosis and Society Thoracic Surgeons score <3 to SAVR versus TAVR with a 2-year primary end point of all-cause mortality and disabling stroke. Both of these trials will include 400 patient substudies of 4DCT to evaluate the incidence of predisposing factors and clinical sequelae of leaflet immobility and valve thrombosis. Whether in an aggregate of 800 patients with low-surgical-risk severe aortic stenosis treatment with either TAVR or SAVR along with protocol-driven surveillance 4DCT imaging with short follow-up will resolve the issues of leaflet immobility and valve thrombosis is a matter of conjecture. Resolution of the multiple issues of aortic valve bioprostheses, both TAVR and SAVR, will have important implications for the growing number of patients who develop significant aortic stenosis as they age.
CLINICAL IMPLICATIONS AND SUMMARY

The relationship between imaging abnormalities
and clinical events remains unclear. 2. The true incidence of these findings remains unknown, but in a recent surveillance study in TAVR with 4DCT imaging was 7%. The risk factors for thrombosis in this group of patients undergoing particularly TAVR with multiple comorbidities remain poorly defined. 3. It is unclear whether this is a device-specific effect or a class finding. All TAVR valves and bioprosthetic SAVR valves should be carefully scrutinized, especially if predisposing factors exist. 4. 4DCT appears to be the most specific and sensitive method of detection, although radiation exposure must be considered. Echocardiography, although widely used, appears to be somewhat less sensitive, although studies on the comparative efficacy of each approach are lacking. 5. Clinicians should be vigilant about possible valve leaflet thrombosis in patients undergoing TAVR or SAVR who experience clinical events such as stroke, persistent or recurrent congestive heart failure, myocardial infarction, or failure to thrive. These patients should undergo 4DCT scanning. 6. Patients with possible risk factors for valve thrombosis or premature structural valve deterioration should be closely scrutinized through appropriate follow-up surveillance programs with more frequent screening. 7. If a leaflet abnormality is detected, a course of anticoagulation before repeat valve replacement should be considered if bleeding risks for the individual patient allow it.
8. Anticoagulation could be considered in the first 3 months after TAVR implantation, similar to clinical recommendations in patients undergoing SAVR. 9. Proposed and ongoing randomized trials evaluating the role of anticoagulation, including novel oral anticoagulant and antiplatelet therapies, should be strongly supported and expeditiously enrolled. 
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